NCT02720198已完成3 期
A Randomized Trial Comparing Efficacy and Tolerability of Levomilnacipran Switch Versus Adjunctive Quetiapine in Major Depressive Disorder (MDD) With Inadequate Response to SSRIs
Duke University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2017年1月23日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Changes of Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
研究概览
简要总结
This study's primary objective is to compare the efficacy and tolerability of switching patients with inadequate relief on generic SSRIs to levomilnacipran versus adding a new treatment (quetiapine) to the participants' existing treatment with people diagnosed with depression (major depression disorder).
The secondary objective is to examine the response and remission rates following the switch from a generic SSRI to levomilnacipran ER and augmentation with quetiapine along with examining changes in neurocognitive and apathy measures after the switch.
详细描述
- Study Design 1) An 8-week, randomized rater blinded parallel group, 2-arm trial 2) Trial duration - 9 weeks 3) Drug doses
- Levomilnacipran ER; Switching to a flexible dose regime of levomilnacipran ER 40-120 mg/day after initial dose of 20mg.
- Quetiapine XR; Adjunct a flexible dose regimen of quetiapine XR 150-300 mg/day after initial dose of 50mg.
- Objective 1) To compare the efficacy and tolerability of switching to levomilnacipran ER (40-120 mg/d) versus augmentation with quetiapine XR 150-300 mg/day to the patients' existing treatment for patients with inadequate relief on generic SSRIs in patients with MDD.
-
To examine the response following the switch from generic SSRI to levomilnacipran ER and augmentation with quetiapine XR.
-
To examine changes in neurocognitive and apathy measures after switching from SSRI to levomilnacipran ER and after augmentation with quetiapine XR in MDD
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-65 years inclusive
- •Current diagnosis of MDD based on DSM-IV criteria
- •Able to understand study rules and procedures and willing to sign written informed consent for study participation
- •Inadequate response to antidepressants: having a score of ≥14 on the 17-item Hamilton Anxiety Scale (HAMD) and not having a ≥ 50% reduction in HAMD or CGI-S scores from baseline after a retrospective confirmation of an adequate trial of a single antidepressant (defined as a minimum 6-week trial of acceptable therapeutic dose (daily dose ≥ 40 mg of fluoxetine, 40 mg of paroxetine, 20 mg of citalopram, 10 mg of escitalopram, 37.5 mg of paroxetine CR, 150 mg of sertraline, 100 mg of fluvoxamine).
- •If female, nonpregnant/nonlactating status
- •Duration of current MDD ≥ 4 weeks and < 24 months
- •Not more than 2 treatment failures of adequate antidepressant trials for current episode of MDD
排除标准
- •Has previously participated in a levomilnacipran ER or quetiapine XR or quetiapine clinical study in previous 12 months
- •Has 1 or more the following:
- •Current or past history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder defined in the DSM- 5
- •Diagnosis of alcohol or other substance use disorder (except nicotine and caffeine) as defined in the DSM-5 that has not been in sustained full remission for at least 6 months prior to screening (participant must also have negative urine drug screen prior to baseline).
- •Presence or history of a clinically significant neurological disorder (including epilepsy)
- •Poorly controlled Hypertension or Diabetes
- •uncontrolled narrow-angle glaucoma
- •hypersensitivity to levomilnacipran, milnacipran , quetiapine or quetiapine XR
- •Neurodegenerative disorder.
- •Has a thyroid stimulating hormone value outside the normal range at the Screening Visit that is deemed clinically significant by the investigator.
- •Has clinically significant abnormal vital signs as determined by the investigator.
- •Has a clinical significant abnormal electrocardiogram.
- •Has screening laboratory values greater than 2.5 times the upper or lower limits of normal range or judged to be clinically significant
- •Has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy or prevent the individual from completing the study.
- •Female subjects of childbearing potential not on adequate contraception methods in the opinion of the investigator
- •o If the female is childbearing, she must agree to use appropriate contraceptive measures for the duration of the study and for one month afterwards. Medically acceptable contraceptives include: (1) surgical sterilization (such as tubal ligation of hysterectomy), (2) approved hormonal contraceptives (such as birth control pills, patches, implants, or injections), (3) barrier methods (such as condom or diaphragm) used with a spermicide, or (4) an intrauterine device (IUD). Contraceptive measures such as Plan B ™, sold for emergency use after unprotected sex, are not acceptable methods for routine use. If the female does become pregnant during this study she must inform the study physician immediately.
- •Has a significant risk of suicide according to Columbia Suicide Severity Rating Scale (CSSRS) or in the clinical judgment of the investigator
- •History of suicide attempt in the previous 12 months
- •MDD with postpartum onset, psychotic features or seasonal features
- •Hamilton Anxiety Scale (HAM-A) baseline score ≥ 24
- •Failure of ≥ 3 adequate trials of different antidepressants for the current episode of MDD
- •≥ 3 episodes major depression in previous 12 months or ≥ 8 lifetime episodes of MDD
- •Current or previous use of an atypical or typical antipsychotic agent for augmentation of major depression or treatment of psychotic depression, mania psychosis, or agitation. Previous use of antipsychotics for insomnia will be permitted.
研究组 & 干预措施
Levomilnacipran
Active Comparator
Levomilnacipran ER is switched from SSRI.
干预措施: Levomilnacipran (Drug)
Quetiapine
Active Comparator
Quetiapine XR is added in addition to current SSRI.
干预措施: Quetiapine (Drug)
结局指标
主要结局
Changes of Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
时间窗: Baseline to Week 8
A ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Total scores will range from 0 to 60. Higher scores indicate greater severity of depressive episodes.
次要结局
- Response Rate(Week 8)
- Remission Rate(Week 8)
- Changes in Neurocognition by Changes in Scores on Reyes Verbal Learning Test(Baseline to Week 8)
- Changes in Neurocognition by Changes in Scores on Scores on Digit Symbol Substitution Test (DSST)(Baseline to Week 8)
- Changes in Sexual Dysfunction by Changes in Scores on Arizona Sexual Experience Scale (ASEX)(Baseline to Week 8)
- Changes of Anxiety Symptoms in Scores on Hamilton Anxiety Rating Scale (HAM-A)(Baseline to Week 8)
- Changes of Quality of Life in Scores on Sheehan Disability Scale (SDS) Total(Baseline to Week 8)
- Changes in Scores on Apathy Evaluation Scale (AES).(Baseline to Week 8)
- Number of Subjects With Global Improvement in Scores on Clinical Global Impression Scale- Severity (CGI-S)(Baseline to Week 8)
- Number of Subjects With General Improvement in Scores on Clinical Global Impression Scale- Improvement (CGI-I)(Baseline to Week 8)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue AdministrationProstate CancerNCT01161563Watson Pharmaceuticals118
已完成
2 期
Repetitive Transcranial Magnetic Stimulation for Treating Resistant Bipolar DepressionBipolar DepressionNCT01586793Douglas Mental Health University Institute8
Unknown
不适用
Morton's Neuroma: Manipulation Versus Steroid InjectionNeuroma, Human ForefootNCT02304094Queen Margaret University64
已完成
3 期
A Comparison of the Effectiveness and Safety of Topiramate and Phenytoin in Patients With New Onset Epilepsy Requiring Rapid Initiation of Antiepileptic Drug TreatmentEpilepsyNCT00210782Johnson & Johnson Pharmaceutical Research & Development, L.L.C.262
终止
4 期
Effects on Postoperative Pain of Liposomal Bupivacaine in Interscalene Blocks for Total Shoulder Arthroplasty PatientsTotal Shoulder ArthroplastyReverse Total Shoulder ArthroplastyNCT05900427Johnny K. Lee78